Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 8;13(11):e0206950. doi: 10.1371/journal.pone.0206950

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Ashton et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 5 — (A) shows a CT axial cross-section through the heart immediately after injection of VHH-AuNPs, demonstrating high CT contrast in the blood after injection. (B) shows the measured enhancement of each contrast agent in the blood over time, along with the exponential fit curve for each nanoparticle type. Enhancement at each time point is normalized to the initial enhancement immediately after injection. All nanoparticles showed an exponential decrease in concentration. C225 had a significantly shorter half-life than VHH-122 or PEG. (C) shows the organ enhancement at 36 hours (relative to the enhancement in the blood immediately after injection) for each contrast agent. C225 showed significantly more spleen accumulation than VHH-122 or PEG. All other differences were not statistically significant.